quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·64d
PRRelease
Serina Therapeutics Inc. logo

Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease

SER· Serina Therapeutics Inc.
Health Care
Original source

Companies

  • SER
    Serina Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Jul 14UpdateH.C. Wainwright$15.00

Related

  • SEC2d
    Serina Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • INSIDER2d
    SEC Form 4 filed by Bailey Gregory
  • INSIDER2d
    SEC Form 4 filed by Venkatesan Jay
  • SEC6d
    SEC Form PRE 14A filed by Serina Therapeutics Inc.
  • PR17d
    Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
  • PR21d
    Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
  • SEC27d
    Amendment: SEC Form 10-K/A filed by Serina Therapeutics Inc.
  • SEC29d
    SEC Form S-8 filed by Serina Therapeutics Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022